We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PAYC:NYSEPaycom Software, Inc. Analysis

Data as of 2026-08-03 - not real-time

$163.96

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Paycom’s stock is trading at $163.96, comfortably above its 20‑day, 50‑day and 200‑day simple moving averages of $147.94, $139.17 and $145.02, indicating recent bullish momentum. The MACD line sits at 6.91 well above its signal at 4.90, supporting the bullish bias, while the RSI of 65.3 hints at modest overbought pressure. However, the 30‑day volatility of roughly 49% and a historical max drawdown of –51% underscore a propensity for sharp swings. The stock faces a clear resistance near $172.54 and support around $132.58, with the next catalyst being the Q2 2026 earnings release slated for August 5. A discounted cash‑flow model values the company at about $99.7, leaving the market price roughly 7.6% above fair value, and analyst price targets (mean $151.5, median $144.5) also sit below the current level. The “Extreme Greed” reading on the Fear & Greed Index (92.9) reflects a highly optimistic market mood that may be pricing in further upside.
On the fundamentals side, Paycom delivers an impressive 87.6% gross margin and a 36.8% operating margin, translating into a 22.4% profit margin and a 37% return on equity. Revenue grew 7.8% YoY to $2.09 billion, and free cash flow of $295 million comfortably funds its modest 0.91% dividend, yielding a low payout ratio of 17%. The balance sheet is leveraged, with $763.6 million of debt versus $153.9 million of cash, resulting in a debt‑to‑equity of about 94, which adds a layer of financial risk. The beta of ~0.8 suggests the stock moves less than the broader market, yet the high volatility and concentration in the U.S. HCM market introduce sector and geographic sensitivities. Given the strong cash generation, high margins, and sustainable dividend, the long‑term outlook remains positive, but the current premium pricing warrants a cautious near‑term stance. Consequently, we recommend holding in the short to medium horizon while positioning for a buy at more attractive valuations over the longer term.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Upcoming Q2 earnings release may trigger volatility
  • RSI indicating overbought conditions
  • Current price above DCF fair value and analyst targets

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Strong operating margins and cash flow generation
  • High leverage requires monitoring
  • Price still above fair value, limiting upside

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Durable SaaS model with high gross and operating margins
  • Sustainable dividend supported by low payout ratio
  • Robust ROE and consistent revenue growth

Key Metrics & Analysis

Financial Health

Revenue Growth7.80%
Profit Margin22.44%
P/E Ratio19.0
ROE37.15%
ROA7.88%
Debt/Equity94.07
P/B Ratio9.2
Op. Cash Flow$710.2M
Free Cash Flow$294.8M
Industry P/E32.8

Technical Analysis

TrendNeutral
RSI65.3
Support$132.58
Resistance$172.54
MA 20$147.94
MA 50$139.17
MA 200$145.02
MACDBullish
VolumeStable
Fear & Greed Index92.88

Valuation

Fair Value$99.72
Target Price$151.50
Upside/Downside-7.60%
GradeOvervalued
TypeBlend
Dividend Yield0.91%

Risk Assessment

Beta0.08
Volatility49.50%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.